Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study
Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial In Recurrent, Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Preview: Corcept Therapeutics’s Earnings
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Corcept Therapeutics will report an earnings per share (EPS) of $0.24.
Corcept Therapeutics Completes Enrollment In Phase 2 GRATITUDE Study Of Miricorilant In Patients With Antipsychotic-Induced Weight Gain
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the
Recap: Corcept Therapeutics Q4 Earnings
Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Corcept Therapeutics Reports Prelim. Results Of Previously-Announced Tender Offer For Up To 10M Shares Of Co. Stock Between $20.75-$23.75/Share In Cash
Corcept Therapeutics Incorporated (NASDAQ:CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by